JP2022524391A5 - - Google Patents
Info
- Publication number
- JP2022524391A5 JP2022524391A5 JP2021553767A JP2021553767A JP2022524391A5 JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5 JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oncolytic virus
- synthetic oncolytic
- synthetic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163492A JP7904878B2 (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815611P | 2019-03-08 | 2019-03-08 | |
| US62/815,611 | 2019-03-08 | ||
| PCT/US2020/013069 WO2020185293A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Division JP7904878B2 (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524391A JP2022524391A (ja) | 2022-05-02 |
| JP2022524391A5 true JP2022524391A5 (cg-RX-API-DMAC7.html) | 2023-01-23 |
| JP7561134B2 JP7561134B2 (ja) | 2024-10-03 |
Family
ID=69526302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553767A Active JP7561134B2 (ja) | 2019-03-08 | 2020-01-10 | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
| JP2024163492A Active JP7904878B2 (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Active JP7904878B2 (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
Country Status (19)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| DK3934673T3 (da) * | 2019-03-08 | 2026-04-07 | Massachusetts Inst Technology | Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN116987736A (zh) * | 2022-03-04 | 2023-11-03 | 上海行深生物科技有限公司 | 自复制rna分子和新冠病毒多价疫苗 |
| AU2023262576A1 (en) | 2022-04-26 | 2024-10-10 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| AU2024208643A1 (en) * | 2023-01-12 | 2025-06-26 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| JP2026513963A (ja) * | 2023-04-07 | 2026-05-01 | フラッグシップ ラブズ 114, インコーポレイテッド | 治療用脂質ナノ粒子(lnp)の送達のための脂質および脂質様化合物 |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| KR20260046366A (ko) | 2023-07-25 | 2026-04-07 | 스트랜드 세러퓨틱스 인코포레이티드 | 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도 |
| CN122319231A (zh) * | 2023-10-27 | 2026-06-30 | 上海元宋生物技术有限公司 | 溶瘤病毒及其用途 |
| WO2026041140A1 (zh) * | 2024-08-23 | 2026-02-26 | 康希诺(上海)生物研发有限公司 | 一种自复制rna分子及其制备方法和应用 |
| CN119479778B (zh) * | 2024-10-16 | 2025-04-25 | 北京悦康科创医药科技股份有限公司 | 一种lnp转染效率预测模型构建方法及装置 |
| WO2026165118A1 (en) | 2025-01-29 | 2026-08-06 | Strand Therapeutics Inc. | Polynucleotides comprising detargeting sensors and uses thereof |
| CN121081290B (zh) * | 2025-11-12 | 2026-03-10 | 佑嘉(杭州)生物医药科技有限公司 | 一种毛囊靶向递送系统及生发防脱化妆品 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| FI4005592T3 (fi) * | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| US11058762B2 (en) * | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| EP2925352B1 (en) * | 2012-12-03 | 2019-10-02 | Ohio State Innovation Foundation | Ehrlichial invasin for immunization, diagnosis, and cell delivery |
| ES2969956T3 (es) * | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| CN122564053A (zh) * | 2014-10-31 | 2026-08-14 | 麻省理工学院 | 递送生物分子至免疫细胞 |
| WO2016187531A1 (en) * | 2015-05-21 | 2016-11-24 | Ohio State Innovation Foundation | Benzene-1,3,5-tricarboxamide derivatives and uses thereof |
| DK3934673T3 (da) | 2019-03-08 | 2026-04-07 | Massachusetts Inst Technology | Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi |
| JP2023535225A (ja) * | 2020-07-24 | 2023-08-16 | ストランド セラピューティクス インコーポレイテッド | 改変ヌクレオチドを含む脂質ナノ粒子 |
| US20240140960A1 (en) * | 2021-02-12 | 2024-05-02 | Ohio State Innovation Foundation | Sugar derived lipid nanomaterials and uses thereof |
| JP2024527345A (ja) * | 2021-07-09 | 2024-07-24 | リプリケイト バイオサイエンス,インコーポレイティド | 改変東部ウマ脳炎ウイルス、自己複製rna構築物、及びその使用 |
| CN117180454A (zh) * | 2022-05-16 | 2023-12-08 | 上海行深生物科技有限公司 | 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法 |
-
2020
- 2020-01-10 DK DK20704372.0T patent/DK3934673T3/da active
- 2020-01-10 EP EP25227099.6A patent/EP4729621A3/en active Pending
- 2020-01-10 CA CA3132714A patent/CA3132714A1/en active Pending
- 2020-01-10 KR KR1020257038746A patent/KR20250171410A/ko active Pending
- 2020-01-10 EP EP20704372.0A patent/EP3934673B1/en active Active
- 2020-01-10 FI FIEP20704372.0T patent/FI3934673T3/fi active
- 2020-01-10 JP JP2021553767A patent/JP7561134B2/ja active Active
- 2020-01-10 AU AU2020233788A patent/AU2020233788A1/en active Pending
- 2020-01-10 US US16/739,407 patent/US11717548B2/en active Active
- 2020-01-10 PT PT207043720T patent/PT3934673T/pt unknown
- 2020-01-10 CN CN202610315107.8A patent/CN122146794A/zh active Pending
- 2020-01-10 CN CN202610315101.0A patent/CN122189105A/zh active Pending
- 2020-01-10 SG SG11202109514VA patent/SG11202109514VA/en unknown
- 2020-01-10 WO PCT/US2020/013069 patent/WO2020185293A1/en not_active Ceased
- 2020-01-10 KR KR1020217032460A patent/KR102889984B1/ko active Active
- 2020-01-10 BR BR112021017637A patent/BR112021017637A8/pt unknown
- 2020-01-10 CN CN202080034343.3A patent/CN113966221B/zh active Active
- 2020-01-10 PH PH1/2021/552145A patent/PH12021552145A1/en unknown
- 2020-01-10 MX MX2021010808A patent/MX2021010808A/es unknown
- 2020-01-10 MY MYPI2021005045A patent/MY207334A/en unknown
- 2020-01-10 ES ES20704372T patent/ES3066636T3/es active Active
-
2021
- 2021-08-30 IL IL285963A patent/IL285963A/en unknown
- 2021-10-07 CO CONC2021/0013417A patent/CO2021013417A2/es unknown
-
2023
- 2023-06-14 US US18/334,449 patent/US12383589B2/en active Active
-
2024
- 2024-09-20 JP JP2024163492A patent/JP7904878B2/ja active Active
-
2025
- 2025-07-09 US US19/264,067 patent/US20260061013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3934673T3 (fi) | Synteettinen onkolyyttinen lnp-replikoni-rna ja sen käyttöjä syövän immunoterapiaan | |
| Yaremenko et al. | Clinical advances of mRNA vaccines for cancer immunotherapy | |
| Huang et al. | A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses | |
| Li et al. | mRNA vaccine in cancer therapy: Current advance and future outlook | |
| Parato et al. | Recent progress in the battle between oncolytic viruses and tumours | |
| Nadeem et al. | A Virus‐Spike Tumor‐Activatable Pyroptotic Agent | |
| Liong et al. | Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery | |
| Ladak et al. | The current Landscape of mRNA vaccines against viruses and cancer–a mini review | |
| Strods et al. | Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications | |
| Zhang et al. | Self‐Oxygenated biomimetic nanozyme for tumor catalytic immunotherapy | |
| Bahreyni et al. | A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy | |
| JP2023535225A5 (cg-RX-API-DMAC7.html) | ||
| Rachamala | Translational advances in lipid nanoparticle drug delivery systems for cancer therapy: current status and future horizons | |
| Hromic-Jahjefendic et al. | Viral vector-based melanoma gene therapy | |
| Vasilevska et al. | Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon | |
| Newman et al. | Infection: a cause of and cure for cancer | |
| Anjum et al. | Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach | |
| Abdessalem et al. | Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells | |
| Ghazizadeh et al. | Advances in cancer nanovaccines: a focus on colorectal cancer | |
| Habibizadeh et al. | Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: a review | |
| Adesokan et al. | SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments | |
| Xing et al. | Research progress of nanoparticles in diagnosis and treatment of hepatocellular carcinoma | |
| Abdel-Rashid et al. | Fabrication of gold nanoparticles in absence of surfactant as in vitro carrier of plasmid DNA | |
| Ermi et al. | Gene therapy strategies for hepatocellular carcinoma (HCC): current landscape and future directions | |
| Joo et al. | Emerging roles of using small extracellular vesicles as an anti-cancer drug |